Note for Favus;
Prior O2 modulators have been very beneficial in improving the disease state. The problem is that they were limited by toxicity and PK. Decreasing painful crises incidences by 80%. Other benefits seen along with decrease in pain.
We know seem to have a once daily oral drug that has a high affinity for hemoglobin and MINIMAL side effects.
After a great 6 months of promising data, looking forward to the Favus update for the Hedgies he advised to go short last year.
#1 Consolidate while doing the hard work from K-Street, usually works. In an election year it will be much harder to slip the 'ole consolidation trick past the public.
Elliot Favus still bashing Global Therapeutics? More likely the news leaking out the past few weeks has pi$$id off the hedges he charges for his "insights".
" hiding 90-day data", LMAO
British Journal of Hematology, nice conservative review. For those following the story there is even more info known info being reviewed, buying all news giving Brexit dips that effect GBT.
Investors that have done their research are now buying as advanced data is released.
What is likely up next?
Among the “2016 Anticipated Milestones” you will find:
Hereditary Angioedema: Complete IND-enabling toxicology studies, submit an IND, and initiate a Phase 1 study for GBT18713, an orally bioavailable kallikrein inhibitor. Expected to start in 2016.
Another promising pipeline drug the company has hight expectations for and would like to some complete research on before being bought out at too cheap of a price.
Global Blood Therapeutics likely has an equally interested domestic buyout? Whoever they pick up will need a knowledgeable worldwide sales force. Any company interested needs to close the deal before "Breakthrough Status" or "accelerated approval" is granted. The price of a buyout will be MUCH higher.
2017 is not that far away and would be much better for tax purposes of many